GB201018149D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number: GB201018149D0
Authority: GB; United Kingdom
Prior art keywords: treatment
Prior art date: 2010-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1018149.3A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2010-10-27

Publication date

2010-12-08

2010-10-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-10-27 Priority to GBGB1018149.3A priority Critical patent/GB201018149D0/en

2010-12-08 Publication of GB201018149D0 publication Critical patent/GB201018149D0/en

2011-10-25 Priority to PCT/EP2011/068674 priority patent/WO2012055879A1/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Transplantation (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB1018149.3A 2010-10-27 2010-10-27 Method of treatment Ceased GB201018149D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1018149.3A GB201018149D0 (en)	2010-10-27	2010-10-27	Method of treatment
PCT/EP2011/068674 WO2012055879A1 (en)	2010-10-27	2011-10-25	Method of treatment by inhibition of baz1b

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1018149.3A GB201018149D0 (en)	2010-10-27	2010-10-27	Method of treatment

Publications (1)

Publication Number	Publication Date
GB201018149D0 true GB201018149D0 (en)	2010-12-08

Family

ID=43365602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1018149.3A Ceased GB201018149D0 (en)	2010-10-27	2010-10-27	Method of treatment

Country Status (2)

Country	Link
GB (1)	GB201018149D0 (en)
WO (1)	WO2012055879A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2907184C (en)	2013-03-15	2022-12-06	Sutter West Bay Hospitals	Falz for use as a target for therapies to treat cancer
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
CN110628898B (en) *	2019-10-23	2022-02-22	中国医学科学院北京协和医院	BAZ1B susceptibility SNP locus detection reagent and kit prepared by same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009099991A2 (en) *	2008-01-31	2009-08-13	The Brigham And Women's Hospital, Inc.	Treatment of cancer
US20100080799A1 (en) *	2008-09-17	2010-04-01	The Rockefeller University	Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity
GB0919432D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use

2010
- 2010-10-27 GB GBGB1018149.3A patent/GB201018149D0/en not_active Ceased
2011
- 2011-10-25 WO PCT/EP2011/068674 patent/WO2012055879A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2012055879A1 (en)	2012-05-03

Publication	Publication Date	Title
GB201110095D0 (en)	2011-07-27	Method of treatment
EP2773754A4 (en)	2015-06-10	Method of treatment
ZA201304280B (en)	2014-08-27	Treatment of jak2-mediated conditions
EP2717855A4 (en)	2014-11-12	Methods of treatment
GB201018147D0 (en)	2010-12-08	Method of treatment
EP2643001A4 (en)	2014-02-19	Method of treating cancer
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2734212A4 (en)	2014-12-24	Methods of treating pain
IL220594A0 (en)	2012-08-30	Treatment method
IL256026B (en)	2019-08-29	Methods of treatment
GB201003920D0 (en)	2010-04-21	Method of treatment
EP2536421A4 (en)	2013-10-09	Method for treatment of psoriasis
GB201018149D0 (en)	2010-12-08	Method of treatment
GB201020045D0 (en)	2011-01-12	Method for the treatment of biogas
EP2585103A4 (en)	2013-09-25	Method of treatment
GB201020015D0 (en)	2011-01-12	Method of treatment
EP2791324A4 (en)	2015-04-29	Method of treatment
GB201005071D0 (en)	2010-05-12	Method of treatment
GB201003917D0 (en)	2010-04-21	Method of treatment
GB201000318D0 (en)	2010-02-24	Method of treatment
GB201111530D0 (en)	2011-08-17	Method of treatment
GB201109509D0 (en)	2011-07-20	Method of treatment
GB201109266D0 (en)	2011-07-20	Method of treatment
GB201103044D0 (en)	2011-04-06	Method of treatment
AU2010900191A0 (en)	2010-02-04	Method of treatment

Legal Events

Date	Code	Title	Description
2012-04-25	AT	Applications terminated before publication under section 16(1)